"We are confident that we followed industry standard and FDA practices and policies fully in processing this tissue and in notifying the proper authorities after learning of the infection. We intend to vigorously defend against this lawsuit and believe that we have adequate insurance coverage for this particular case."
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community. For additional information about CryoLife please visit http://www.cryolife.com.
Statements made in this press release that look forward in time or that
express management's beliefs, expectations or hopes are forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. These statements include those regarding the potential outcome
of the litigation described above. These future events may not occur as and
when expected, if at all, and, together with the Company's business, are
subject to various risks and uncertainties. These risks and uncertainties
include the uncertainties surrounding the trial of any litigation, the
|SOURCE CryoLife, Inc.|
Copyright©2008 PR Newswire.
All rights reserved